Patents by Inventor Mei-Yun Zhang
Mei-Yun Zhang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11124561Abstract: Provided herein are HIV-1-specific transforming antibodies (tAbs) and antigens that are recognized by HIV-1-specific tAbs. Also provided herein are methods for screening and/or generating HIV-1-specific tAbs and uses of tAbs for prevention and treatment of HIV-1 infection.Type: GrantFiled: March 4, 2019Date of Patent: September 21, 2021Assignee: THE UNIVERSITY OF HONG KONGInventor: Mei-Yun Zhang
-
Publication number: 20190185549Abstract: Provided herein are HIV-1-specific transforming antibodies (tAbs) and antigens that are recognized by HIV-1-specific tAbs. Also provided herein are methods for screening and/or generating HIV-1-specific tAbs and uses of tAbs for prevention and treatment of HIV-1 infection.Type: ApplicationFiled: March 4, 2019Publication date: June 20, 2019Inventor: Mei-Yun Zhang
-
Patent number: 10280213Abstract: Provided herein are HIV-1-specific transforming antibodies (tAbs) and antigens that are recognized by HIV-1-specific tAbs. Also provided herein are methods for screening and/or generating HIV-1-specific tAbs and uses of tAbs for prevention and treatment of HIV-1 infection.Type: GrantFiled: June 27, 2012Date of Patent: May 7, 2019Assignee: THE UNIVERSITY OF HONG KONGInventor: Mei-Yun Zhang
-
Patent number: 9481729Abstract: Disclosed are antibodies, or binding fragments thereof, that specifically bind to human HER2 and human IGF-IR. Also provided are nucleic acid molecules encoding the disclosed antibodies and binding fragments and vectors and host cells containing these nucleic acid molecules. The disclosure also provides methods of inhibiting cancer cell growth and metastasis in a mammal using the antibodies described herein, as well as compositions containing the antibodies, nucleic acid molecules encoding the antibodies, and host cells and vectors comprising the nucleic acid molecules. The disclosure also features the use of the polypeptides to detect the presence of HER2 and IGF-IR in a mammal, and epitopes that can be used as cancer vaccine immunogens.Type: GrantFiled: September 11, 2014Date of Patent: November 1, 2016Assignee: The University of Hong KongInventor: Mei-Yun Zhang
-
Publication number: 20150071927Abstract: Disclosed are antibodies, or binding fragments thereof, that specifically bind to human HER2 and human IGF-IR. Also provided are nucleic acid molecules encoding the disclosed antibodies and binding fragments and vectors and host cells containing these nucleic acid molecules. The disclosure also provides methods of inhibiting cancer cell growth and metastasis in a mammal using the antibodies described herein, as well as compositions containing the antibodies, nucleic acid molecules encoding the antibodies, and host cells and vectors comprising the nucleic acid molecules. The disclosure also features the use of the polypeptides to detect the presence of HER2 and IGF-IR in a mammal, and epitopes that can be used as cancer vaccine immunogens.Type: ApplicationFiled: September 11, 2014Publication date: March 12, 2015Inventor: Mei-Yun Zhang
-
Patent number: 8444982Abstract: The subject invention provides antibodies, or binding fragments thereof, that specifically bind to human IGF-IR. Also provided are nucleic acid molecules encoding the antibodies and binding fragments of the subject invention and vectors and host cells containing these nucleic acid molecules. The disclosure also provides methods of inhibiting cancer cell growth and metastasis in a mammal using the antibodies described herein, as well as compositions containing the antibodies, nucleic acid molecules encoding the antibodies, and host cells and vectors comprising the nucleic acid molecules. The disclosure also features the use of the polypeptides to detect the presence of IGF-IR in a mammal, and epitopes that can be used as cancer vaccine immunogens.Type: GrantFiled: November 29, 2010Date of Patent: May 21, 2013Assignee: The University of Hong KongInventor: Mei-Yun Zhang
-
Publication number: 20130011414Abstract: Provided herein are HIV-1-specific transforming antibodies (tAbs) and antigens that are recognized by HIV-1-specific tAbs. Also provided herein are methods for screening and/or generating HIV-1-specific tAbs and uses of tAbs for prevention and treatment of HIV-1 infection.Type: ApplicationFiled: June 27, 2012Publication date: January 10, 2013Applicant: University of Hong KongInventor: Mei-Yun Zhang
-
Patent number: 8110192Abstract: The present invention provides an antibody to human immunodeficiency virus (HIV) envelope glycoprotein that can recognize one or more strains of HIV, wherein the epitope of HIV recognized by the antibody is inducible, and wherein the antibody binding to the epitope is enhanced by the presence of CD4 and the HIV co-receptor, and related fusion proteins, conjugates, nucleic acids, vectors, host cells, compositions and methods of use to inhibit an infection of a human at risk of becoming infected with HIV, to reduce the severity of an infection of a human infected with HIV, and to treat an infection of a human with HIV.Type: GrantFiled: July 24, 2009Date of Patent: February 7, 2012Assignee: The United States of America, as represented by the Secretary, Department of Health and Human ServicesInventors: Dimiter S. Dimitrov, Mei-Yun Zhang
-
Publication number: 20110135663Abstract: The subject invention provides antibodies, or binding fragments thereof, that specifically bind to human IGF-IR. Also provided are nucleic acid molecules encoding the antibodies and binding fragments of the subject invention and vectors and host cells containing these nucleic acid molecules. The disclosure also provides methods of inhibiting cancer cell growth and metastasis in a mammal using the antibodies described herein, as well as compositions containing the antibodies, nucleic acid molecules encoding the antibodies, and host cells and vectors comprising the nucleic acid molecules. The disclosure also features the use of the polypeptides to detect the presence of IGF-IR in a mammal, and epitopes that can be used as cancer vaccine immunogens.Type: ApplicationFiled: November 29, 2010Publication date: June 9, 2011Applicant: THE UNIVERSITY OF HONG KONGInventor: MEI-YUN ZHANG
-
Publication number: 20100317837Abstract: The present invention provides a method of identifying novel broadly crossreactive neutralizing monoclonal antibodies using sequential antigen panning of phage display libraries, antibodies obtained in accordance with such a method, as well as fusion proteins and conjugates comprising same, and related isolated or purified nucleic acid molecules, vectors, host cells, compositions, and methods of use to inhibit an infection, reduce the severity of an infection, treat an infection, and inhibit cancer.Type: ApplicationFiled: August 26, 2010Publication date: December 16, 2010Applicant: The United States of America, as represented by the Secretary, Dep. of Health and Human ServicesInventors: Dimiter S. Dimitrov, Mei-Yun Zhang
-
Patent number: 7803913Abstract: The present invention provides a method of identifying novel broadly crossreactive neutralizing monoclonal antibodies using sequential antigen panning of phage display libraries, antibodies obtained in accordance with such a method, as well as fusion proteins and conjugates comprising same, and related isolated or purified nucleic acid molecules, vectors, host cells, compositions, and methods of use to inhibit an infection, reduce the severity of an infection, treat an infection, and inhibit cancer.Type: GrantFiled: May 6, 2003Date of Patent: September 28, 2010Assignee: The United States of America as represented by the Department of Health and Human ServicesInventors: Dimiter S Dimitrov, Mei-Yun Zhang
-
Publication number: 20090291493Abstract: The present invention provides an antibody to human immunodeficiency virus (HIV) envelope glycoprotein that can recognize one or more strains of HIV, wherein the epitope of HIV recognized by the antibody is inducible, and wherein the antibody binding to the epitope is enhanced by the presence of CD4 and the HIV co-receptor, and related fusion proteins, conjugates, nucleic acids, vectors, host cells, compositions and methods of use to inhibit an infection of a human at risk of becoming infected with HIV, to reduce the severity of an infection of a human infected with HIV, and to treat an infection of a human with HIV.Type: ApplicationFiled: July 24, 2009Publication date: November 26, 2009Applicant: The U.S.A, as represented by the Secretary, Department of Health and Human ServicesInventors: Dimiter S. Dimtrov, Mei-Yun Zhang
-
Patent number: 7566451Abstract: The present invention provides an antibody to human immunodeficiency virus (HIV) envelope glycoprotein that can recognize one or more strains of HIV, wherein the epitope of HIV recognized by the antibody is inducible, and wherein the antibody binding to the epitope is enhanced by the presence of CD4 and the HIV co-receptor, and related fusion proteins, conjugates, nucleic acids, vectors, host cells, compositions and methods of use to inhibit an infection of a human at risk of becoming infected with HIV, to reduce the severity of an infection of a human infected with HIV, and to treat an infection of a human with HIV.Type: GrantFiled: May 6, 2003Date of Patent: July 28, 2009Assignee: The United States of America as represented by the Department of Health and Human ServicesInventors: Dimiter S. Dimitrov, Mei-Yun Zhang
-
Patent number: 7378093Abstract: The present invention features antibodies and antibody fragments that specifically bind a CD4-inducible HIV gp120 epitope that is enhanced by binding a co-receptor for HIV, such as CCR5 or CXCR4, and pharmaceutical compositions comprising the antibodies or antibody fragments. The invention also features nucleic acids encoding the antibodies or antibody fragments, pharmaceutical compositions comprising the nucleic acids encoding the antibodies or antibody fragments, vectors comprising the nucleic acids, and cells comprising the vectors. The invention further features methods of identifying antibodies or antibody fragments with broadly neutralizing activity against HIV. The invention also features methods of inhibiting HIV entry into cells and methods of inhibiting replication of HIV in mammals, using the antibodies and nucleic acids of the invention.Type: GrantFiled: May 15, 2007Date of Patent: May 27, 2008Assignees: The United States of America as represented by the Department of Health and Human Services, The Scripps Research InstituteInventors: Dimiter S. Dimitrov, Maxime Moulard, Xiadong Xiao, Yuuei Shu, Sanjay K. Phogat, Mei-Yun Zhang, Dennis Burton
-
Publication number: 20080038280Abstract: The invention provides a fusion protein, which comprises an antigen binding portion of an A32 human antibody, or variant thereof, and one of the following: (a) an antigen-binding portion of a second antibody or variant thereof, wherein the second antibody binds to an epitope of an envelope protein of a human immunodeficiency virus (HIV) that is exposed upon the HIV binding to a CD4 receptor, (b) an immunogenic portion of an envelope protein of a HIV, or a variant thereof, or (c) a soluble CD4 (sCD4) polypeptide capable of binding to HIV, or a or variant thereof.Type: ApplicationFiled: October 11, 2005Publication date: February 14, 2008Applicant: Government of the United States of AmericaInventors: Dimiter Dimitrov, Mei-Yun Zhang
-
Publication number: 20070292390Abstract: The invention provides polypeptides that bind with an epitope of the gp41 subunit of the HIV-1 envelope glycoprotein, as well as polypeptides comprising the aforementioned epitopes. The invention also provides methods of inhibiting an HIV infection in a mammal using the polypeptides of the invention, as well as compositions comprising the polypeptides, nucleic acid molecules encoding the polypeptides, and host cells and vectors comprising the nucleic acid molecules. A method of isolating antibodies that bind with an epitope of the gp41 subunit of the HIV-1 envelope glycoprotein using competitive antigen panning (CAP) is also provided. The invention also features the use of the polypeptides to detect the presence of HIV in a mammal, and epitopes that can be used as vaccine immunogens.Type: ApplicationFiled: October 28, 2005Publication date: December 20, 2007Inventors: Dimiter Dimitrov, Mei-Yun Zhang
-
Publication number: 20070212349Abstract: The present invention features antibodies and antibody fragments that specifically bind a CD4-inducible HIV gp120 epitope that is enhanced by binding a co-receptor for HIV, such as CCR5 or CXCR4, and pharmaceutical compositions comprising the antibodies or antibody fragments. The invention also features nucleic acids encoding the antibodies or antibody fragments, pharmaceutical compositions comprising the nucleic acids encoding the antibodies or antibody fragments, vectors comprising the nucleic acids, and cells comprising the vectors. The invention further features methods of identifying antibodies or antibody fragments with broadly neutralizing activity against HIV. The invention also features methods of inhibiting HIV entry into cells and methods of inhibiting replication of HIV in mammals, using the antibodies and nucleic acids of the invention.Type: ApplicationFiled: May 15, 2007Publication date: September 13, 2007Applicants: GOVERNMENT OF THE UNITED STATES OF AMERICA, REPRESENTED BY THE SECRETARY, DEPARTMENT, THE SCRIPPS RESEARCH INSTITUTEInventors: Dimiter Dimitrov, Maxime Moulard, Xiadong Xiao, Yuuei Shu, Sanjay Phogat, Mei-Yun Zhang, Dennis Burton
-
Publication number: 20070212363Abstract: A (poly)peptide-Fc fusion molecule, such as an scFv-Fc fusion molecule comprising an scFv fragment and an Fc region from an antibody, related nucleic acids, vectors, and host cells, and a method of inhibiting a viral infection in a mammal, which method comprises administering to a mammal in need thereof the fusion molecule, wherein the fusion molecule binds to an epitope of a viral envelope protein that is inaccessible to whole immunoglobulin molecules due to molecular steric hindrance, or a nucleic acid, optionally in the form of a vector, encoding same, wherein the nucleic acid or vector is optionally contained within a host cell.Type: ApplicationFiled: September 29, 2004Publication date: September 13, 2007Applicant: The Gov of USA, as Represented by the Secretary, Dept. of Health and Human ServicesInventors: Dimiter Dimitrov, Mei-Yun Zhang
-
Patent number: 7223844Abstract: The present invention features antibodies and antibody fragments that specifically bind a CD4-inducible HIV gp120 epitope that is enhanced by binding a co-receptor for HIV, such as CCR5 or CXCR4, and pharmaceutical compositions comprising the antibodies or antibody fragments. The invention also features nucleic acids encoding the antibodies or antibody fragments, pharmaceutical compositions comprising the nucleic acids encoding the antibodies or antibody fragments, vectors comprising the nucleic acids, and cells comprising the vectors. The invention further features methods of identifying antibodies or antibody fragments with broadly neutralizing activity against HIV. The invention also features methods of inhibiting HIV entry into cells and methods of inhibiting replication of HIV in mammals, using the antibodies and nucleic acids of the invention.Type: GrantFiled: October 16, 2002Date of Patent: May 29, 2007Assignees: United States of America, Represented by the Secretary, Department of Health and Human Services, Scripps Research InstituteInventors: Dimiter S. Dimitrov, Maxime Moulard, Xiadong Xiao, Yuuei Shu, Sanjay K. Phogat, Mei-Yun Zhang, Dennis Burton
-
Publication number: 20050164166Abstract: The present invention provides an antibody to human immunodeficiency virus (HIV) envelope glycoprotein that can recognize one or more strains of HIV, wherein the epitope of HIV recognized by the antibody is inducible, and wherein the antibody binding to the epitope is enhanced by the presence of CD4 and the HIV co-receptor, and related fusion proteins, conjugates, nucleic acids, vectors, host cells, compositions and methods of use to inhibit an infection of a human at risk of becoming infected with HIV, to reduce the severity of an infection of a human infected with HIV, and to treat an infection of a human with HIV.Type: ApplicationFiled: May 6, 2003Publication date: July 28, 2005Applicant: Government of the United States of America represented by the Secreatary, Dept of Health ServInventors: Dimiter Dimitrov, Mei-Yun Zhang